Literature DB >> 22343177

Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy.

George K Siberry1, D Robert Harris, Ricardo Hugo Oliveira, Margot R Krauss, Cristina B Hofer, Adriana Aparecida Tiraboschi, Heloisa Marques, Regina C Succi, Thalita Abreu, Marinella Della Negra, Lynne M Mofenson, Rohan Hazra.   

Abstract

BACKGROUND: This study evaluated a wide range of viral load (VL) thresholds to identify a cut-point that best predicts new clinical events in children on stable highly active antiretroviral therapy (HAART).
METHODS: Cox proportional hazards modeling was used to assess the adjusted risk for World Health Organization stage 3 or 4 clinical events (WHO events) as a function of time-varying CD4, VL, and hemoglobin values in a cohort study of Latin American children on HAART ≥6 months. Models were fit using different VL cut-points between 400 and 50,000 copies per milliliter, with model fit evaluated on the basis of the minimum Akaike information criterion value, a standard model fit statistic.
RESULTS: Models were based on 67 subjects with WHO events out of 550 subjects on study. The VL cut-points of >2600 and >32,000 copies per milliliter corresponded to the lowest Akaike information criterion values and were associated with the highest hazard ratios (2.0, P = 0.015; and 2.1, P = 0.0058, respectively) for WHO events.
CONCLUSIONS: In HIV-infected Latin American children on stable HAART, 2 distinct VL thresholds (>2600 and >32,000 copies/mL) were identified for predicting children at significantly increased risk for HIV-related clinical illness, after accounting for CD4 level, hemoglobin level, and other significant factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343177      PMCID: PMC3360833          DOI: 10.1097/QAI.0b013e31824e4da6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.

Authors:  W T Shearer; T C Quinn; P LaRussa; J F Lew; L Mofenson; S Almy; K Rich; E Handelsman; C Diaz; M Pagano; V Smeriglio; L A Kalish
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

2.  Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.

Authors:  Ricardo Oliveira; Margot Krauss; Suzanne Essama-Bibi; Cristina Hofer; D Robert Harris; Adriana Tiraboschi; Ricardo de Souza; Heloisa Marques; Regina Succi; Thalita Abreu; Marinella Della Negra; Rohan Hazra; Lynne M Mofenson; George K Siberry
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

3.  Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.

Authors:  Asgeir Johannessen; Carolina Garrido; Natalia Zahonero; Leiv Sandvik; Ezra Naman; Sokoine L Kivuyo; Mabula J Kasubi; Svein G Gundersen; Johan N Bruun; Carmen de Mendoza
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

4.  Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.

Authors:  P E Palumbo; C Raskino; S Fiscus; S Pahwa; M G Fowler; S A Spector; J A Englund; C J Baker
Journal:  JAMA       Date:  1998-03-11       Impact factor: 56.272

5.  The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.

Authors:  L M Mofenson; J Korelitz; W A Meyer; J Bethel; K Rich; S Pahwa; J Moye; R Nugent; J Read
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

6.  First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Authors:  Abdel Babiker; Hannah Castro nee Green; Alexandra Compagnucci; Susan Fiscus; Carlo Giaquinto; Diana M Gibb; Lynda Harper; Linda Harrison; Michael Hughes; Ross McKinney; Ann Melvin; Lynne Mofenson; Yacine Saidi; M Elizabeth Smith; Gareth Tudor-Williams; A Sarah Walker
Journal:  Lancet Infect Dis       Date:  2011-01-31       Impact factor: 25.071

  6 in total
  2 in total

1.  Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time.

Authors:  Elijah Paintsil; Ryan Martin; Ariel Goldenthal; Shreya Bhandari; Warren Andiman; Musie Ghebremichael
Journal:  J AIDS Clin Res       Date:  2016-04-14

2.  Correlates of High HIV Viral Load and Antiretroviral Therapy Adherence Among Viremic Youth in the United States Enrolled in an Adherence Improvement Intervention.

Authors:  K Rivet Amico; Jessica Crawford; Ini Ubong; Jane C Lindsey; Aditya H Gaur; Keith Horvath; Rachel Goolsby; Megan Mueller Johnson; Ronald Dallas; Barbara Heckman; Teresa Filipowicz; Melissa Polier; Betty M Rupp; Michael Hudgens
Journal:  AIDS Patient Care STDS       Date:  2021-05       Impact factor: 5.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.